US Biosimilar Outlook: Inspections, Interchangeability And Positioning For The Post-Humira Era
Executive Summary
Six of the 10 biosimilar candidates under FDA review are waiting on inspections delayed by COVID-19; in the meantime, sponsors jockey for position when Humira biosimilar launch windows open up next year.
You may also be interested in...
Coherus: Interchangeability ‘A Melting Ice Cube,’ Price And Supply Key
Coherus’ manufacturing scale for its Yusimry adalimumab biosimilar means it will “be able to drive the price down and to be able to provide supply guarantees,” management has insisted during a recent investor conference. “We think this will be very, very important.”
Alvotech Humira Settlement Sets Up Interchangeable Adalimumab Showdown
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.
Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership
Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.